FindTrial
Sign In

Growth and pubertal development in Girls with turner syndrome.

Clinical and cytogenetic profile of Turner syndrome: growth and pubertal outcomes. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/06/112190
Enrollment
57
Registered
2026-06-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Q960- Karyotype 45, X Health Condition 2: Q961- Karyotype 46, X iso (Xq) Health Condition 3: Q963- Mosaicism, 45, X/46, XX or XY Health Condition 4: Q964- Mosaicism, 45, X/other cell line(s) with abnormal sex chromosome Health Condition 5: Q968- Other variants of Turners syndrome Health Condition 6: Q969- Turners syndrome, unspecified

Interventions

Intervention1: Nil: Nil

Sponsors

Dr U Parthasarathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All karyotypically proven cases of Turner syndrome.

Exclusion criteria

Exclusion criteria: Other syndromic and non-Turner etiology short statures, chromosomal abnormalities other than Turner syndrome, severe systemic comorbid illness, history of malignancy or prior chemo/radiotherapy, chronic systemic corticosteroids or immunosuppressant use, premature ovarian failure with XX, and short stature with XX.

Design outcomes

Primary

MeasureTime frame
To correlate cytogenetic patterns with clinical and systemic manifestations, To evaluate growth hormone therapy response (height velocity, height SDS). Timepoint: 2 years—

Secondary

MeasureTime frame
To correlate karyotype with growth hormone responseTimepoint: 2 years—

Countries

India

Contacts

Public ContactDr U Parthasarathy

Madurai medical college

drsridharjipmer@gmail.com9789720246

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026